This project has been flagged by a community member as inappropriate due to reason below.*

Expert Interview

Slingshot members are talking to an expert! The topic is:

Discussing therapies in development for Congenital Adrenal Hyperplasia (CAH) including Neurocrine Biosciences' gene therapy Crinecerfont

Ticker(s): NBIX

Who's the expert?

Institution:  University of Tennessee

  • Professor of Medicine & Chief of the Section of Endrocrinology at the University of Tennessee Graduate School of Medicine at Knoxville & Founding Partner of Endocrinology Consultants of East Tennessee (private practice).
  • Currently manages 5 patients with CAH.
  • Fellowship trained at the Mayo Clinic and lead author of more than ten original research articles published in a number of leading medical journals, including the New England Journal of Medicine, Annals of Internal Medicine, Journal of Clinical Investigation, Journal of Clinical Endocrinology and Metabolism, Endocrine Practice, the American Journal of Medicine, and the Mayo Clinic Proceedings.

Interview Goal
This conversation will focus on the potential of gene therapy in treating Congenital Adrenal Hyperplasia with a specific focus on Neurocrine's Crinecerfont.

Are You Interested In These Questions?

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.

Reason

*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.